Claims for Patent: 6,126,946

Summary for Patent: 6,126,946

Title:	Hepatocyte-selective oil-in-water emulsion
Abstract:	A heat and shelf-stable oil-in-water emulsion useful as a tissue or cell-selective delivery vehicle. Radioactive or stable, synthetic or semi-synthetic polyhalogenated triglycerides, such as 2-oleoylglycerol-1,3-bis[7-(3-amino-2,4,6-triiodophenyl)heptanoate] or 2-oleoylglycerol-1,3-bis[.omega.-(3,5-bis-trifluoromethyl)hepatanoate] or phenyl acetate, can be incorporated into the lipophilic core of a lipoprotein-like emulsion particle. The lipophilic core is surrounded by a phospholipid membrane comprising cholesterol and apolipoproteins. For hepatocyte-selective delivery, the emulsion is chylomicron remnant-like by being in a size range of 50 to 200 nm as measured by number weighting analysis with a narrow size distribution (<2% greater than 300 nm) and having a composition simulating naturally-occurring chylomicron remnants. Use of cholesterol in the emulsion formula facilitates association of apolipoproteins, especially Apo E which are recognized by liver cells and necessary for binding and uptake. Stability and size constraints can be achieved by using ultra high energy mixing equipment, such as such as the MicroFluidizer (Microfluidics Corp., Newton, Mass.) to form the emulsion. In preferred embodiments, osmolality of the emulsion is controlled by glycerol rather than normal saline.
Inventor(s):	Counsell; Raymond E. (Ann Arbor, MI), Longino; Marc A. (Ann Arbor, MI), Weichert; Jamey P. (Ann Arbor, MI), Bakan; Douglas A. (Ann Arbor, MI)
Assignee:	University of Michigan, The Board of Regents (Ann Arbor, MI)
Application Number:	08/899,411
Patent Claims:	1. A heat stable oil-in-water emulsion comprising: a) up to 50% (w/v) pharmaceutically acceptable fat or oil of natural, synthetic, or semi-synthetic origin which is a pharmacologically inert nonpolar lipid and/or a lipophilic or amphipathic diagnostic, therapeutic, or biologically active or inactive agent; b) up to 10% (w/v) phospholipid emulsifier; c) up to about 5% (w/v) cholesterol; d) up to 5% (w/v) of an osmolality adjusting agent; and e) the remainder of the emulsion being sterile water, the emulsion having a mean particle diameter of the oil phase between 50 to 200 nm with greater than 98% of the particles being less than 300 nm, and being able to withstand heat sterilization without a significant change in mean particle size distribution and without losing its ability to associate with apoprotein E so as to be hepatocyte-selective. 2. The oil-in-water emulsion of claim 1 wherein the pharmaceutically acceptable fat or oil comprises between about 10% and 30% (w/v) of the emulsion. 3. The oil-in-water emulsion of claim 1 wherein the lipophilic or amphipathic agent is a pharmaceutically acceptable nonpolar lipid. 4. The oil-in-water emulsion of claim 3 wherein the pharmaceutically acceptable nonpolar lipid is a triglyceride. 5. The oil-in-water emulsion of claim 4 wherein the triglyceride is an oil of animal or vegetable origin selected from the group consisting of soybean oil, safflower oil, cottonseed oil, and fish oils. 6. The oil-in-water emulsion of claim 4 wherein the triglyceride is a synthetic or semi-synthetic lipid. 7. The oil-in-water emulsion of claim 6 wherein the synthetic or semi-synthetic lipid is triolein. 8. The oil-in-water emulsion of claim 6 wherein the triglyceride is an halogenated triglyceride. 9. The oil-in-water emulsion of claim 1 wherein the pharmaceutically acceptable fat or oil comprises at least one pharmacologically inert nonpolar lipid and a lipophilic or amphipathic agent. 10. The oil-in-water emulsion of claim 9 wherein the pharmaceutically acceptable fat or oil comprises at least one pharmacologically inert nonpolar lipid and an halogenated triglyceride. 11. The oil-in-water emulsion of claim 1 wherein between about 2.4% and 4.8% (w/v) of the emulsion is the phospholipid emulsifier. 12. The oil-in-water emulsion of claim 1 wherein the phospholipid emulsifier is synthetic or semi-synthetic. 13. The oil-in-water emulsion of claim 12 wherein the phospholipid emulsifier is dioleoylphosphatidylcholine. 14. The oil-in-water emulsion of claim 1 wherein the emulsion includes a sufficient amount of the osmolality adjusting agent to obtain an osmolality of between 400-500 mOsm/kg. 15. The oil-in-water emulsion of claim 14 wherein the osmolality adjusting agent is anhydrous glycerol. 16. The hepatocyte-selective oil-in-water emulsion of claim 1 further containing an antioxidant. 17. The oil-in-water emulsion of claim 16 wherein the antioxidant is .alpha.-tocopherol. 18. A method of treating a living being in need of treatment comprising the step of administering an effective amount of the oil-in-water emulsion of claim 1 which contains a therapeutically active lipophilic or amphipathic agent.

Details for Patent 6,126,946

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2014-05-16